Now Comes The Hard Part: Sandoz Must Sell Its Biosimilar
March 6, 2015
The Pink Sheet
Axinn Counsel Stacie Ropka was quoted in The Pink Sheet’s article, “Now Comes the Hard Part: Sandoz Must Sell Its Biosimilar.” The Pink Sheet is produced by Pharma & Med Tech Business Intelligence.
Click here to access the article. A subscription is required.